News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dowpharma (DOW) Announces Agreement With Pfizer Inc. (PFE) Using Pfenex Expression Technology(TM) And Dow Solvent Extraction Technology


10/19/2005 5:12:56 PM

MIDLAND, Mich., March 7 /PRNewswire/ -- Dowpharma(SM), a business unit of The Dow Chemical Company, announced today that it has entered into an agreement with Pfizer Inc to develop a cell line using Pfenex Expression Technology(TM), a Pseudomonas-based technology from Dowpharma.

Under the terms of the agreement, Pfizer will fund efforts at Dowpharma to evaluate the production of a Pfizer therapeutic protein using Pfenex Expression Technology(TM), as well as the use of a Dow proprietary solvent extraction technology. Additional financial details of the agreement were not disclosed.

"This agreement demonstrates the interest of the biopharmaceutical industry in producing therapeutic proteins using an expression system that delivers higher yields and process technologies that can reduce the overall cost of goods for biotherapeutics," said Nick Hyde, business director, Dowpharma. "In the cases that we have tested, Pfenex consistently outperforms other commercially available microbial expression systems such as E. coli."

Pfenex Expression Technology(TM) is built around specially modified strains of Pseudomonas fluorescens bacteria that increase cellular expression while maintaining critical solubility and activity characteristics of recombinantly expressed therapeutic proteins.

"This agreement allows Pfizer, the world's largest pharmaceutical company, to leverage the resources and technologies of the world's largest chemical company. We believe our customized solutions and full spectrum of services will continue to meet and exceed the needs of our customers," said Hyde.

About Dowpharma

Dowpharma(SM) serves the pharmaceutical and biopharmaceutical industries with innovative technologies, products, and services in drug discovery, development, delivery and manufacturing. With over three decades of experience, Dowpharma combines the resources and capabilities of several offerings to create a single-market-focused organization with broad service and support capabilities for large and emerging pharmaceutical companies. For more information on Dowpharma, visit http://www.dowpharma.com/ .

About Dow

Dow is a leader in science and technology, providing innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $40 billion, Dow serves customers in 175 countries and a wide range of markets that are vital to human progress: food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of sustainable development, Dow and its 43,000 employees seek to balance economic, environmental and social responsibilities. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. For more information on The Dow Chemical Company, visit http://www.dow.com/ .

(SM) Service Mark of The Dow Chemical Company

(TM) Trademark of The Dow Chemical Company

The Dow Chemical Company

CONTACT: Kathleen Davis of The Dow Chemical Company, +1-989-636-2760,kadavis@dow.com ; or Josiah McClellan of Gibbs & Soell, +1-212-697-2600jmcclellan@gibbs-soell.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES